




Instance: composition-en-9a27641c92c3b8f37c07af63ced02da9
InstanceOf: CompositionUvEpi
Title: "Composition for riluzole Package Leaflet"
Description:  "Composition for riluzole Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp426b2c49d3a7ba14afc86e203bc29cab)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - riluzole"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Riluzole Zentiva is and what it is used for </li>
<li>What you need to know before you take Riluzole Zentiva </li>
<li>How to take Riluzole Zentiva </li>
<li>Possible side effects </li>
<li>How to store Riluzole Zentiva </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What riluzole is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What riluzole is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Riluzole Zentiva is </p>
<p>The active substance in Riluzole Zentiva is riluzole which acts on the nervous system. </p>
<p>What Riluzole Zentiva is used for </p>
<p>Riluzole Zentiva is used in patients with amyotrophic lateral sclerosis (ALS). </p>
<p>ALS is a form of motor neurone disease where attacks of the nerve cells responsible for sending 
instructions to the muscles lead to weakness, muscle waste and paralysis. </p>
<p>The destruction of nerve cells in motor neurone disease may be caused by too much glutamate (a 
chemical messenger) in the brain and spinal cord. Riluzole Zentiva stops the release of glutamate and 
this may help in preventing the nerve cells being damaged. </p>
<p>Please consult your doctor for more information about ALS and the reason why this medicine has been 
prescribed for you. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take riluzole"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take riluzole"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Riluzole Zentiva 
- if you are allergic to riluzole or any of the other ingredients of this medicine (listed in section 
6), 
- if you have any liver disease or increased blood levels of some enzymes of the liver 
(transaminases), 
- if you are pregnant or breast-feeding. </p>
<p>Warnings and precautions 
Talk to your doctor before taking Riluzole Zentiva:</p>
<ul>
<li>if you have any liver problems: yellowing of your skin or the white of your eyes (jaundice), 
itching all over, feeling sick, being sick </li>
<li>if your kidneys are not working very well </li>
<li>if you have any fever: it may be due to a low number of white blood cells which can cause an 
increased risk of infection 
If any of the above applies to you, or if you are not sure, tell your doctor who will decide what to 
do. </li>
</ul>
<p>Children and adolescents 
If you are less than 18 years of age, the use of Riluzole Zentiva is not recommended because there is 
no information available in this population. </p>
<p>Other medicines and Riluzole Zentiva 
Tell your doctor if you are taking, have recently taken or might take any other medicines. </p>
<p>Pregnancy, breast-feeding and fertility 
You MUST NOT take Riluzole Zentiva if you are or think you may be pregnant, or if you are 
breast-feeding. </p>
<p>If you think you may be pregnant, or if you intend to breast-feed, ask your doctor for advice before 
taking Riluzole Zentiva. </p>
<p>Driving and using machines 
You can drive or use any tools or machines, unless you feel dizzy or light headed after taking this 
medicine. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take riluzole"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take riluzole"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure.  </p>
<p>The recommended dose is one tablet, twice a day.<br />
The tablets should be taken by mouth, every 12 hours, at the same time of the day each day (e.g. in the 
morning and evening). </p>
<p>If you take more Riluzole Zentiva than you should </p>
<p>If you take too many tablets, contact your doctor or the nearest hospital emergency department 
immediately.  </p>
<p>If you forget to take Riluzole Zentiva </p>
<p>If you forget to take your tablet, leave out that dose completely and take the next tablet at the usual 
time. 
Do not take a double dose to make up for a forgotten tablet. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>IMPORTANT 
Tell your doctor immediately 
- if you experience any fever (increase in temperature) because Riluzole Zentiva may cause a 
decrease in the number of white blood cells. Your doctor may want to take a blood sample to 
check the number of white blood cells, which are important in fighting infections. </p>
<ul>
<li>
<p>if you experience any of the following symptoms: yellowing of your skin or the white of your 
eyes (jaundice), itching all over, feeling sick, being sick, as this may be signs of liver disease 
(hepatitis).Your doctor may do regular blood tests while you are taking Riluzole Zentiva to 
make sure that this does not occur. </p>
</li>
<li>
<p>if you experience cough or difficulties in breathing, as this may be a sign of lung disease (called 
interstitial lung disease).  </p>
</li>
</ul>
<p>Other side effects 
Very common side effects (may affect more than 1 in 10 people) of Riluzole Zentiva are:</p>
<ul>
<li>tiredness  </li>
<li>feeling sick  </li>
<li>increased blood levels of some enzymes of the liver (transaminases).  </li>
</ul>
<p>Common side effects (may affect up to 1 in 10 people) of Riluzole Zentiva are:</p>
<ul>
<li>dizziness </li>
<li>numbness or tingling of the mouth </li>
<li>vomiting </li>
<li>sleepiness </li>
<li>increase in heart beat </li>
<li>diarrhoea </li>
<li>headache </li>
<li>abdominal pain </li>
<li>pain </li>
</ul>
<p>Uncommon side effects (may affect up to 1 in 100 people) of Riluzole Zentiva are:</p>
<ul>
<li>anaemia  </li>
<li>allergic reactions  </li>
<li>inflammation of the pancreas (pancreatitis).  </li>
</ul>
<p>Not known effects (frequency cannot be estimated from the available data) of Riluzole Zentiva are:</p>
<ul>
<li>rash </li>
</ul>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store riluzole"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store riluzole"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. 
The expiry date refers to the last day of that month.  </p>
<p>This medicine does not require any special storage conditions. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Riluzole Zentiva contains </p>
<ul>
<li>The active substance is riluzole. </li>
<li>The other ingredients are: 
Core: anhydrous dibasic calcium phosphate, micro crystalline cellulose, anhydrous colloidal silica, 
magnesium stearate, croscarmellose sodium; 
Coating: hypromellose, macrogol 6000, titanium dioxide (E171). </li>
</ul>
<p>What Riluzole Zentiva looks like and content of the pack </p>
<p>The tablets are film-coated, capsule-shaped and white. Each tablet contains 50 mg of riluzole and is 
engraved with  RPR 202  on one side. 
Riluzole Zentiva is available in a pack of 28, 56, 98, 112 or 168 tablets to be taken orally. 
Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Zentiva k.s.<br />
U kabelovny 102 37 Prague Czech Republic </p>
<p>Manufacturers 
Opella Healthcare International SAS 
56, Route de Choisy 
60200 Compi gne 
France </p>
<p>For any information about this medicinal product, please contact the local representative of the 
Marketing Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Zentiva, k.s. 
T l/Tel: +32 280 86 PV-Belgium@zentiva.com </p>
<p>Lietuva 
Zentiva, k.s. 
Tel: +370 52152PV-Lithuania@zentiva.com </p>
<p>Zentiva, k.s. 
 : +35924417PV-Bulgaria@zentiva.com </p>
<p>Luxembourg/Luxemburg 
Zentiva, k.s. 
T l/Tel: +352 208 82PV-Luxembourg@zentiva.com 
 esk  republika 
Zentiva, k.s. 
Tel: +420 267 241 PV-Czech-Republic@zentiva.com 
Magyarorsz g 
Zentiva Pharma Kft. 
Tel.: +36 1 299 1PV-Hungary@zentiva.com 
Danmark 
Zentiva Denmark ApS 
Tlf: +45 787 68 PV-Denmark@zentiva.com </p>
<p>Malta 
Zentiva, k.s. 
Tel: +356 277 82 PV-Malta@zentiva.com 
Deutschland 
Zentiva Pharma GmbH<br />
Tel: +49 (0) 800 53 53 PV-Germany@zentiva.com </p>
<p>Nederland 
Zentiva, k.s. 
Tel: +31 202 253 PV-Netherlands@zentiva.com 
Eesti 
Zentiva, k.s. 
Tel: +372 52 70PV-Estonia@zentiva.com </p>
<p>Norge 
Zentiva Denmark ApS 
Tlf: +47 219 66 PV-Norway@zentiva.com </p>
<p>Zentiva, k.s. 
 : +30 211 198 7PV-Greece@zentiva.com </p>
<p>sterreich 
Zentiva, k.s. 
Tel: +43 720 778 PV-Austria@zentiva.com 
Espa a 
Zentiva, k.s. 
Tel: +34 931 815 PV-Spain@zentiva.com </p>
<p>Polska 
Zentiva Polska Sp. z o.o. 
Tel: + 48 22 375 92 PV-Poland@zentiva.com 
France 
Zentiva France 
T l: +33 (0) 800 089 PV-France@zentiva.com </p>
<p>Portugal 
Zentiva Portugal, Lda 
Tel: +351210601PV-Portugal@zentiva.com 
Hrvatska 
Zentiva d. o. o. 
Tel: +385 1 6641 PV-Croatia@zentiva.com </p>
<p>Ireland 
Zentiva, k.s. 
Tel: +353 766 803 PV-Ireland@zentiva.com </p>
<p>Rom nia 
ZENTIVA S.A. 
Tel: +4 021.304.7PV-Romania@zentiva.com </p>
<p>Slovenija 
Zentiva, k.s. 
Tel: +386 360 00 PV-Slovenia@zentiva.com 
 sland 
Zentiva Denmark ApS 
S mi: +354 539 0PV-Iceland@zentiva.com </p>
<p>Slovensk  republika 
Zentiva, a.s. 
Tel: +421 2 3918 3PV-Slovakia@zentiva.com 
Italia 
Zentiva Italia S.r.l. 
 +39-02-38598PV-Italy@zentiva.com 
Suomi/Finland 
Zentiva Denmark ApS 
Puh/Tel: +358 942 598 PV-Finland@zentiva.com </p>
<p>Zentiva, k.s. 
 : +357 240 30 PV-Cyprus@zentiva.com </p>
<p>Sverige 
Zentiva Denmark ApS 
Tel: +46 840 838 PV-Sweden@zentiva.com 
Latvija 
Zentiva, k.s. 
Tel: +371 67893PV-Latvia@zentiva.com 
United Kingdom (Northern Ireland) 
Zentiva, k.s. 
Tel: +44 (0) 800 090 2PV-United-Kingdom@zentiva.com </p>
<p>This leaflet was last approved in {MM/YYYY}. </p>
<p>Annex IV 
Scientific conclusions and grounds for the variation to the terms of the marketing 
authorisation(s) </p>
<p>Scientific conclusions 
Taking into account the PRAC Assessment Report on the PSUR(s) for riluzole, the scientific 
conclusions of CHMP are as follows:<br />
In view of available data on rash from spontaneous reports including in some cases a close temporal 
relationship, a positive de-challenge and/or re-challenge, the PRAC concluded that a causal 
relationship between riluzole and rash is at least a reasonable possibility and the product 
information of products containing riluzole should be amended accordingly. </p>
<p>The CHMP agrees with the scientific conclusions made by the PRAC. </p>
<p>Grounds for the variation to the terms of the marketing authorisation(s) 
On the basis of the scientific conclusions for riluzole the CHMP is of the opinion that the benefit-
risk balance of the medicinal product(s) containing riluzole is unchanged subject to the proposed 
changes to the product information 
The CHMP recommends that the terms of the marketing authorisation(s) should be varied. </p>         </div>"""      



Instance: composition-da-9a27641c92c3b8f37c07af63ced02da9
InstanceOf: CompositionUvEpi
Title: "Composition for riluzole Package Leaflet"
Description:  "Composition for riluzole Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp426b2c49d3a7ba14afc86e203bc29cab)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - riluzole"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse<br />
2. Det skal du vide, før du begynder at tage Riluzole Zentiva 
3. Sådan skal du tage Riluzole Zentiva<br />
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What riluzole is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What riluzole is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvad Riluzole Zentiva er </p>
<p>Det aktive indholdsstof i Riluzole Zentiva er riluzol, som virker på nervesystemet. </p>
<p>Hvad Riluzole Zentiva anvendes til </p>
<p>Riluzole Zentiva anvendes til patienter med amyotrofisk lateral sclerose (ALS). </p>
<p>ALS er en form for motor-neuronsygdom, hvor angreb på de nerveceller, der er ansvarlige for at sende 
instruktioner til musklerne, fører til muskelsvaghed, muskeltab og lammelse. </p>
<p>Ødelæggelsen af nervecellerne i motor-neuronsygdomme kan skyldes for meget glutamat (et kemisk 
stof) i hjernen og rygmarven. Riluzole Zentiva forhindrer frigivelsen af glutamat og dette kan hjælpe 
med at forebygge, at nerveceller bliver ødelagt.<br />
Få mere information hos din læge om ALS og hvorfor du får denne medicin </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take riluzole"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take riluzole"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Riluzole Zentiva 
- hvis du er allergisk over for riluzol eller et af de øvrige indholdsstoffer i Riluzole Zentiva 
(angivet i punkt 6). 
- hvis du har en leversygdom eller forhøjede niveauer af visse lever-enzymer (aminotransferaser) 
i blodet. 
- hvis du er gravid eller ammer. </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, før du tager Riluzole Zentiva:</p>
<ul>
<li>hvis du har nogen form for leverproblemer: gulfarvning af huden eller det hvide i dine øjne 
(gulsot), kløe over det hele, kvalme, opkastning </li>
<li>
<p>hvis dine nyrer ikke fungerer normalt </p>
</li>
<li>
<p>hvis du får feber. Dette kan være et tegn på et fald i antallet af hvide blodlegemer, som kan 
medføre forøget risiko for infektion 
Hvis du oplever noget af ovenstående, eller hvis du føler dig usikker, så fortæl det til din læge, 
som vil beslutte, hvad der skal gøres. </p>
</li>
</ul>
<p>Børn og unge<br />
Hvis du er under 18 år, anbefales det ikke, at du tager Riluzole Zentiva, da der ikke er nogen 
information tilgængelig for denne patientgruppe. </p>
<p>Brug af anden medicin sammen med Riluzole Zentiva 
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for 
nylig.  </p>
<p>Graviditet, amning og frugtbarhed 
Du må ikke tage Riluzole Zentiva, hvis du er gravid eller ammer, eller har mistanke om, at du er 
gravid. </p>
<p>Hvis du har mistanke om, du er gravid, eller hvis du overvejer at amme, skal du spørge din læge til 
råds, før du tager Riluzole Zentiva.  </p>
<p>Trafik- og arbejdssikkerhed 
Du kan køre bil og anvende værktøj og maskiner, når du tager Riluzole Zentiva, medmindre du føler 
dig svimmel eller omtåget. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take riluzole"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take riluzole"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller 
apotekspersonalet. </p>
<p>Den anbefalede dosis er 1 tablet to gange om dagen.<br />
Du bør indtage tabletterne oralt hver 12. time, på samme tidspunkt af dagen hver dag (for eksempel 
om morgenen og om aftenen). </p>
<p>Hvis du har taget for mange Riluzole Zentiva 
Hvis du har taget for mange tabletter, skal du straks kontakte din læge eller skadestue. </p>
<p>Hvis du har glemt at tage Riluzole Zentiva 
Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om.  </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>VIGTIGT 
Kontakt straks din læge 
- hvis du får nogen form for feber (forhøjet temperatur), da Riluzole Zentiva kan medføre 
nedsættelse af antallet af hvide blodlegemer. Din læge kan ønske at tage blodprøver for at 
kontrollere antallet af hvide blodlegemer, som er vigtige for at kunne bekæmpe infektioner. </p>
<ul>
<li>
<p>hvis du får nogen af følgende symptomer: Gulfarvning af huden eller det hvide i øjnene 
(gulsot), kløe over hele kroppen, kvalme eller kaster op, da dette kan være tegn på 
leverbetændelse (hepatitis). Din læge kan udføre regelmæssige blodprøver, mens du får 
Riluzole Zentiva, for at sikre sig, at dette ikke sker. </p>
</li>
<li>
<p>hvis du får hoste eller besvær med at trække vejret, da dette kan være tegn på en lungesygdom 
(som hedder interstitiel lungesygdom). </p>
</li>
</ul>
<p>Andre bivirkninger 
Meget almindelige bivirkninger (kan forekomme hos mere end 1 ud af 10 personer) af Riluzole 
Zentiva er:</p>
<ul>
<li>træthed </li>
<li>kvalme </li>
<li>forføjet niveau af nogle enzymer (aminotransferaser) i blodet. </li>
</ul>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer) af Riluzole Zentiva er:</p>
<ul>
<li>svimmelhed </li>
<li>prikken i munden </li>
<li>opkastning </li>
<li>søvnighed </li>
<li>hurtigere hjerterytme </li>
<li>diarré </li>
<li>hovedpine </li>
<li>mavesmerter </li>
<li>smerter </li>
</ul>
<p>Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer) af Riluzole Zentiva er:</p>
<ul>
<li>blodmangel </li>
<li>allergiske reaktioner </li>
<li>betændelse i bugspytkirtlen (pancreatitis) </li>
</ul>
<p>Ikke kendt (kan ikke estimeres ud fra forhåndenværende data):</p>
<ul>
<li>udslæt </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan 
også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store riluzole"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store riluzole"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter Exp. Udløbsdatoen er den 
sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige opbevaringsbetingelser. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Riluzole Zentiva indeholder:</p>
<ul>
<li>Aktivt stof: Riluzol. </li>
<li>Øvrige indholdsstoffer: 
Kerne: vandfri calciumphosphat, mikrokrystallinsk cellulose, vandfri kolloid silica, magnesiumstearat, 
samt croscarmellosenatrium. 
Overtræk: hypromellose, macrogol 6000 og titandioxid (E171). </li>
</ul>
<p>Udseende og pakningsstørrelser 
Tabletterne er filmovertrukne, kapselformede og hvide. Hver tablet indeholder 50 mg riluzol og har 
“RPR 202" præget på den ene side af tabletten. 
Riluzole Zentiva fås i en pakning med 28, 56, 98, 112 eller 168 tabletter til oral anvendelse. 
Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Zentiva k.s.<br />
U kabelovny 130<br />
102 37 Prag Tjekkiet </p>
<p>Fremstiller 
Opella Healthcare International SAS 
56, Route de Choisy 
60200 Compiègne 
Frankrig </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen. </p>
<p>België/Belgique/Belgien 
Zentiva, k.s. 
Tél/Tel: +32 280 86 PV-Belgium@zentiva.com </p>
<p>Lietuva 
Zentiva, k.s. 
Tel: +370 52152PV-Lithuania@zentiva.com 
България 
Zentiva, k.s. 
Тел: +35924417PV-Bulgaria@zentiva.com </p>
<p>Luxembourg/Luxemburg 
Zentiva, k.s. 
Tél/Tel: +352 208 82PV-Luxembourg@zentiva.com 
Česká republika 
Zentiva, k.s. 
Tel: +420 267 241 PV-Czech-Republic@zentiva.com 
Magyarország 
Zentiva Pharma Kft. 
Tel.: +36 1 299 1PV-Hungary@zentiva.com 
Danmark 
Zentiva Denmark ApS 
Tlf: +45 787 68 PV-Denmark@zentiva.com </p>
<p>Malta 
Zentiva, k.s. 
Tel: +356 277 82 PV-Malta@zentiva.com 
Deutschland 
Zentiva Pharma GmbH<br />
Tel: +49 (0) 800 53 53 PV-Germany@zentiva.com </p>
<p>Nederland 
Zentiva, k.s. 
Tel: +31 202 253 PV-Netherlands@zentiva.com 
Eesti 
Zentiva, k.s. 
Tel: +372 52 70PV-Estonia@zentiva.com </p>
<p>Norge 
Zentiva Denmark ApS 
Tlf: +47 219 66 PV-Norway@zentiva.com 
Ελλάδα 
Zentiva, k.s. 
Τηλ: +30 211 198 7PV-Greece@zentiva.com </p>
<p>Österreich 
Zentiva, k.s. 
Tel: +43 720 778 PV-Austria@zentiva.com 
España 
Zentiva, k.s. 
Tel: +34 931 815 PV-Spain@zentiva.com </p>
<p>Polska 
Zentiva Polska Sp. z o.o. 
Tel: + 48 22 375 92 PV-Poland@zentiva.com </p>
<p>France 
Zentiva France 
Tél: +33 (0) 800 089 219<br />
PV-France@zentiva.com </p>
<p>Portugal 
Zentiva Portugal, Lda 
Tel: +351210601PV-Portugal@zentiva.com 
Hrvatska 
Zentiva d. o. o. 
Tel: +385 1 6641 PV-Croatia@zentiva.com </p>
<p>Ireland 
Zentiva, k.s. 
Tel: +353 766 803 PV-Ireland@zentiva.com </p>
<p>România 
ZENTIVA S.A. 
Tel: +4 021.304.7PV-Romania@zentiva.com </p>
<p>Slovenija 
Zentiva, k.s. 
Tel: +386 360 00 PV-Slovenia@zentiva.com 
Ísland 
Zentiva Denmark ApS 
Sími: +354 539 0PV-Iceland@zentiva.com </p>
<p>Slovenská republika 
Zentiva, a.s. 
Tel: +421 2 3918 3PV-Slovakia@zentiva.com 
Italia 
Zentiva Italia S.r.l. 
 +39-02-38598PV-Italy@zentiva.com 
Suomi/Finland 
Zentiva Denmark ApS 
Puh/Tel: +358 942 598 PV-Finland@zentiva.com </p>
<p>Κύπρος 
Zentiva, k.s. 
Τηλ: +357 240 30 PV-Cyprus@zentiva.com </p>
<p>Sverige 
Zentiva Denmark ApS 
Tel: +46 840 838 PV-Sweden@zentiva.com 
Latvija 
Zentiva, k.s. 
Tel: +371 67893PV-Latvia@zentiva.com 
United Kingdom (Northern Ireland) 
Zentiva, k.s. 
Tel: +44 (0) 800 090 2PV-United-Kingdom@zentiva.com </p>
<p>Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ} </p>
<p>Bilag IV </p>
<p>Videnskabelige konklusioner og begrundelser for ændring af betingelserne 
for markedsføringstilladelsen/-tilladelserne </p>
<p>Videnskabelige konklusioner </p>
<p>Under hensyntagen til PRAC's vurderingsrapport om PSUR'en/PSUR'erne for riluzol er CHMP nået 
frem til følgende videnskabelige konklusioner: </p>
<p>I betragtning af tilgængelige data for udslæt fra spontane rapporter, inklusive tilfælde med en tæt 
tidsmæssig sammenhæng, positiv de-challenge (symptomerne forsvandt ved seponering) og/eller 
positiv re-challenge (symptomerne kom tilbage ved re-eksponering) konkluderede PRAC, at en kausal 
sammenhæng mellem riluzol og udslæt i det mindste er en rimelig mulighed, og at 
produktinformationen for produkter indeholdende riluzol bør ændres i overensstemmelse hermed. </p>
<p>CHMP tilslutter sig PRAC's videnskabelige konklusioner. </p>
<p>Begrundelser for ændring af betingelserne for markedsføringstilladelsen/-tilladelserne </p>
<p>På baggrund af de videnskabelige konklusioner for riluzol er CHMP af den opfattelse, at benefit/risk-
forholdet for det lægemiddel/de lægemidler, der indeholder riluzol, forbliver uændret under 
forudsætning af, at de foreslåede ændringer indføres i produktinformationen. </p>
<p>CHMP anbefaler, at betingelserne for markedsføringstilladelsen/-tilladelserne bør ændres. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-9a27641c92c3b8f37c07af63ced02da9
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for riluzole Package Leaflet for language en"
Description: "ePI document Bundle for riluzole Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-9a27641c92c3b8f37c07af63ced02da9"
* entry[0].resource = composition-en-9a27641c92c3b8f37c07af63ced02da9

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp9a27641c92c3b8f37c07af63ced02da9"
* entry[=].resource = mp9a27641c92c3b8f37c07af63ced02da9
                            
                    
Instance: bundlepackageleaflet-da-9a27641c92c3b8f37c07af63ced02da9
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for riluzole Package Leaflet for language da"
Description: "ePI document Bundle for riluzole Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-9a27641c92c3b8f37c07af63ced02da9"
* entry[0].resource = composition-da-9a27641c92c3b8f37c07af63ced02da9

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp9a27641c92c3b8f37c07af63ced02da9"
* entry[=].resource = mp9a27641c92c3b8f37c07af63ced02da9
                            
                    



Instance: mp9a27641c92c3b8f37c07af63ced02da9
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Riluzole Zentiva 50 mg film-coated tablets"
Description: "Riluzole Zentiva 50 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/12/768/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Riluzole Zentiva 50 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 9a27641c92c3b8f37c07af63ced02da9ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "riluzole"

* status = #current
* mode = #working

* title = "List of all ePIs associated with riluzole"

* subject = Reference(mp426b2c49d3a7ba14afc86e203bc29cab)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#riluzole "riluzole"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-9a27641c92c3b8f37c07af63ced02da9) // riluzole en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-9a27641c92c3b8f37c07af63ced02da9) // riluzole da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-9a27641c92c3b8f37c07af63ced02da9
InstanceOf: List

* insert 9a27641c92c3b8f37c07af63ced02da9ListRuleset
    